OVERVIEW

Beyond Statins: Therapies to Decrease Cardiovascular Risk is organized by Baptist Health South Florida and will be held from May 01, 2018 - May 01, 2020.

Target Audience:
Cardiologists, Interventional Cardiologists, Interventional Radiologists, General Internists, Primary Care Physicians, Intensivists, General Surgeons, Gynecologists, Anesthesiologists, Emergency Medicine Physicians, Hospitalists, Nurses, Nurse Practitioners, Pharmacists and other interested healthcare providers.

Accreditation:
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• 1.00 AMA PRA Category 1 Credit.
• 1.00 Florida Board of Nursing.
• 1.00 Nurse Practitioners.
• 1.00 Florida Board of Pharmacy.
• 1.00 General certificate of attendance.

Conference Description:
PCSK9 is an established target for cholesterol-lowering therapies. Further study of PCSK9 regulatory mechanisms may identify additional control points for pharmacological inhibition of PCSK9-mediated LDLR degradation. PCSK9 function could reflect ancient roles in the fasting-feeding cycle and in linking lipoprotein metabolism with innate immunity. Dr. Peter A. McCullough will discuss the regulatory function of PCSK9, as well as results from recent clinical trials on the efficacy and safety of PCSK9.

Learning Objectives:
• Review global cardiovascular risk.
• Demonstrate the regulatory function of PCSK9.
• Synthesize the results of randomized trials with respect to efficacy and safety of PCSK9.

Additional details will be posted as soon as they are available.